AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Long Term Debt

Last Annual Value

96.37M

3-Year CAGR

%

5-Year CAGR

67%

10-Year CAGR

%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Long Term Debt

SPRY · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
96.37M
N/A81.2%N/A 
3.44M
-20.9%-26.7%-11.7%
SVRA logo
Savara Inc.
NASDAQ:SVRA
29.91M
4.3%11.5%24.1%
9.71M
1.3%N/A2.9%
431.00K
N/AN/AN/A
350.00K
N/AN/AN/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
0.00
N/AN/AN/A
5.34M
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07